Articular nociception induced by endothelin-1, carrageenan and LPS in naive and previously inflamed knee-joints in the rat: Inhibition by endothelin receptor antagonists

Pain

Volumn 77, Issue 3, 1998, Pages 261-269

  De Melo, Josélia Daher ^a,b   Tonussi, Carlos Rogério ^a   D'Orléans Juste, Pedro ^c   Rae, Giles Alexander ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b STATE UNIVERSITY OF PONTA GROSSA   (Brazil)

^c UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Arthritis; Articular; Bosentan; BQ 123; BQ 788; Carrageenan; Endothelin; LPS; Nociception; Pain

Indexed keywords

BOSENTAN; CARRAGEENAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; LIPOPOLYSACCHARIDE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; SARAFOTOXIN S6C;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; INTRAARTICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KNEE ARTHRITIS; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTHRITIS, REACTIVE; CARRAGEENAN; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; EXCIPIENTS; KNEE JOINT; LIPOPOLYSACCHARIDES; MALE; NOCICEPTORS; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, ENDOTHELIN; SULFONAMIDES; VASOCONSTRICTOR AGENTS; VIPER VENOMS;

EID: 0032168433     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(98)00098-0     Document Type: Article

References (57)

1. Basbaum A.I., Levine J.D. The contribution of the nervous system to inflammation and inflammatory disease. Can. J. Physiol. Pharmacol. 69:1991;647-651.
2. Battistini B., Forget M., Laight D. Potential roles for endothelins in systemic inflammatory response syndrome with a particular relationship to cytokines. Shock. 3:1996;167-183.
3. Bertelli A., Clerico A., Chicca A., Giovannini L., Gorio A., Romano M.A. Role of endothelin-1 in carrageenan-induced inflammation. Int. J. Tissue React. 14:1992;225-230.
4. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 389:1997;816-824.
5. Chiou W.J., Magnuson S.R., Dixon D., Sundy S., Opgenorth T.J., Wu-Wong J.R. Dissociation characteristics of endothelin receptor agonists and antagonists in cloned human type-B endothelin receptor. Endothelium. 5:1997;179-189.
6. Clozel M., Breu V., Gray G.A., Kalina B., Löffler B.M., Burri K., Cassal J.M., Hirth G., Müller M., Neidhart W., Ramuz H. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270:1994;228-235.
7. Cunha F.Q., Poole S., Lorenzetti B.B., Ferreira S.H. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br. J. Pharmacol. 107:1992;660-664.
8. Cunningham M.E., Huribal M., Bala R.J., McMillen M.A. Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines. Crit. Care Med. 25:1997;958-964.
9. Cutolo M., Sulli A., Seriolo B., Accardo S. Macrophages, synovial tissue and rheumatoid arthritis. Clin. Exp. Rheumatol. 11:1993;331-339.
10. Damon D.H. Postganglionic sympathetic neurons express endothelin. Am. J. Physiol. 274:1998;R873-R878.
11. Dardick S.J., Basbaum A.I., Levine J.D. The contribution of pain to disability in experimentally induced arthritis. Arthr. Rheum. 29:1986;1017-1022.
12. De-Melo J.D., Tonussi C.R., D'Orleans-Juste P., Rae G.A. Effects of endothelin-1 on inflammatory incapacitation in the rat knee joint. J. Cardiovasc. Pharmacol. 31(suppl. 1):1998;518-520.
13. Ehrenreich H., Anderson R.W., Fox C.H., Rieckmann P., Hoffman G.S., Travis W.D., Coligan J.E., Kehrl J.H., Fauci A.S. Endothelins, peptides with potent vasoconstrictive properties, are produced by human macrophages. J. Exp. Med. 172:1990;1741-1748.
14. Ferreira S.H., Romitelli M., De Nucci G. Endothelin-1 participation in overt and inflammatory pain. J. Cardiovasc. Pharmacol. 13(suppl. 5):1989;220-222.
15. Fitzgerald M. Arthritis and the nervous system. Tr. Neurosci. 12:1989;86-87.
16. Frelin C., Guedin D. Why are circulating concentrations of endothelin-1 so low? Cardiovasc. Res. 28:1994;1613-1622.
17. Guerne P.A., Weisman M.H. Palindromic rheumatism: part of or apart from the spectrum of rheumatoid arthritis. Am. J. Med. 93:1992;451-460.
18. Gutierrez S., Palacios I., Egido J., Gomez-Garre D., Hernandez P., Gonzalez E., Herrero-Beaumont G. Endothelin-1 induces loss of proteoglycans and enhances fibronectin and collagen production in cultured rabbit synovial cells. Eur. J. Pharmacol. 302:1996;191-197.
19. Helset E., Kjaeve J., Hauge A. Endothelin-1-induced increases in microvascular permeability in isolated, perfused rat lungs requires leukocytes and plasma. Circ. Shock. 39:1993;15-20.
20. Heumann D., Bas S., Gallay P., Le Roy D., Barras C., Mensi N., Glauser M.P., Vischer T. Lipopolysaccharide binding protein as a marker of inflammation in synovial fluid of patients with arthritis: correlation with interleukin-6 and C-reactive protein. J. Rheumatol. 22:1995;1224-1229.
21. Hyslop S., De Nucci G. Vasoactive mediators released by endothelins. Pharmacol. Res. 26:1992;223-242.
22. International Association for Studies of Pain, Ethical guidelines for investigations of experimental pain in conscious animals, Pain, 16 (1983) 109-110.
23. A receptor. J. Cardiovasc. Pharmacol. 12(suppl.12):1992;11-14.
24. Ishikawa K., Ihara M., Noguchi K., Mase T., Mino N., Saeki T., Fukuroda T., Fukami T., Ozaki S., Nagase T., Nishikibe M., Yano M. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc. Natl. Acad. Sci. USA. 91:1994;4892-4896.
25. Keefe F.J., van Horn Y. Cognitive-behavioral treatment of rheumatoid arthritis pain: maintaining treatment gains. Arthr. Care Res. 6:1993;213-222.
26. Khatib A.M., Lomri A., Moldovan F., Fiet J., Mitrovic D.R. Constitutive and inducible expression of endothelin-1 in primary rat articular chondrocyte culture. Cytokine. 9:1997;556-562.
27. Klemm P., Warner T.D., Corder R., Vane J.R. Endothelin-1 mediates coronary vasoconstriction caused by exogenous and endogenous cytokines. J. Cardiovasc. Pharmacol. 26(suppl. 3):1995;410-421.
28. Kobayashi Y., Sakamoto Y., Shibasaki M., Kimura I., Matsuo H. Human alveolar macrophages synthesize endothelins by thrombin. J. Immunol. 158:1997;5442-5447.
29. Landis C.A., Robinson C.R., Levine J.D. Sleep fragmentation in the arthritic rat. Pain. 34:1988;93-99.
30. Levine, J.D., Dardick, S.J., Roizen, M.F., Helms, C. and Basbaum, A.I., Contribution of sensory afferents and sympathetic efferents to joint injury in experimental arthritis, J. Neurosci., 6 (1986a) 3423-3429.
31. Levine, J.D., Fye, K., Heller, P., Basbaum, A.I. and Whiting-O'Keefe, Q., Clinical response to regional intravenous guanethidine in patients with rheumatoid arthritis, J. Rheumatol., 13 (1986b) 1040-1043.
32. Maeda S., Miyauchi T., Goto K., Matsuda M. Differences in the change in the time course of plasma endothelin-1 and endothelin-3 levels after exercise in humans. The responses to exercise of endothelin-3 is more rapid than that of endothelin-1. Life Sci. 61:1997;419-425.
33. Masaki T., Vane J.R., Vanhoutte P.M. International Union of Pharmacology nomenclature of endothelin receptors. Pharmacol. Rev. 46:1994;137-142.
34. Miyasaka N., Hirata Y., Ando K., Sato K., Morita H., Shichiri M., Kanno K., Tomito K., Marumo F. Increased production of endothelin-1 in patients with inflammatory arthritides. Arthr. Rheumat. 35:1992;397-400.
35. Nahir A., Hoffman A., Lorber M., Keiser H.R. Presence of immunoreactive endothelin in synovial fluid: analysis of 22 cases. J. Rheumatol. 18:1991;678-680.
36. Piovezan, A.P., D'Orléans-Juste, P., Tonussi, C.R. and Rae, G.A., Effects of endothelin-1 on capsaicin-induced nociception in mice, Eur. J. Pharmacol., 1998 (In Press).
37. Rae, G.A. and Henriques, M.G.M.O., Endothelins in inflammation. In: S. Said (Ed.), Pro-inflammatory and Anti-inflammatory Peptides, Dekker, New York, 1998, pp. 163-202.
38. Raffa R.B., Schupsky J.J., Lee D.K., Jacoby H.I. Characterization of endothelin-induced nociception in mice: evidence for a mechanistically distinct analgesic model. J. Pharmacol. Exp. Ther. 278:1996;1-7.
39. Sartor R.B. Importance of intestinal mucosal immunity and luminal bacterial cell wall polymers in the aetiology of inflammatory joint diseases. Baillieres Clin. Rheumatol. 3:1989;223-245.
40. Schwarting A., Schlaak J., Lotz J., Pfers I., Meyer-zum-Buschenfelde K.H., Mayet W.J. Endothelin-1 modulates the expression of adhesion molecules on fibroblast-like synovial cells (FLS). Scand. J. Rheumatol. 25:1996;246-256.
41. Sessa W.C., Kaw S., Hecker M., Vane J.R. The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem. Biophys. Res. Commun. 174:1991;613-618.
42. Stankova J., D'Orleans-Juste P., Rola-Pleszczynski M. ET-1 induces IL-6 gene expression in human umbilical vein endothelial cells: synergistic effect of IL-1. Am. J. Physiol. 271:1996;C1073-C1078.
43. Steen K.H., Steen A.E., Kreysel H.W., Reeh P.W. Inflammatory mediators potentiate pain induced by experimental tissue acidosis. Pain. 66:1996;163-170.
44. Stojilkovic S.S., Vukicevic S., Luyten F.P. Calcium signalling in endothelin- and platelet-derived growth factor-stimulated chondrocytes. J. Bone Miner. Res. 9:1994;705-714.
45. Sugiura M., Inagami T., Kon V. Endotoxin stimulates endothelin-release in vivo and in vitro as determined by radioimmunoassay. Biochem. Biophys. Res. Commun. 161:1989;1220-1227.
46. Tonussi C.R., Ferreira S.H. Rat knee-joint carrageenan incapacitation test: an objective screen for central and peripheral analgesics. Pain. 48:1992;421-427.
47. Uslu T., Erem C., Tosum M., Deger O. Plasma endothelin-1 levels in Behcet's disease. Clin. Rheumatol. 16:1997;59-61.
48. van Lent P.L., Holthuysen A.E., van den Bersselaar L., van Rooijen N., van de Putte L.B., van den Berg W.B. Role of macrophage-like synovial lining cells in localization and expression of experimental arthritis. Scand. J. Rheumatol. 101:1995;83-89.
49. Vemulapalli S., Chiu P.J., Rivelli M., Foster C.J., Sybertz E.J. Modulation of circulating endothelin levels in hypertension and endotoxemia in rats. J. Cardiovasc. Pharmacol. 18(suppl.):1991;895-903.
50. Wharton J., Rutherford R.A., Walsh D.A., Mapp P.I., Knock G.A., Blake D.R., Polak J.M. Autoradiographic localization and analysis of endothelin-1 binding sites in human synovial tissues. Arthr. Rheum. 35:1992;894-899.
51. Watkins L.R., Maier S.F., Goehler L.E. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain. 63:1995;289-302.
52. Webb D.J. Endothelin: from molecule to man. Br. J. Clin. Pharmacol. 44:1997;9-20.
53. Webb M.L., Meek T.D. Inhibitors of endothelin, Med. Res. Rev. 17:1997;17-67.
54. A receptor agonists and antagonists. J. Cardiovasc. Pharmacol. 26(Suppl. 3):1995;380-384.
55. Yamamoto T., Shimoyama N., Asano H., Mizuguchi T. Analysis of the role of endothelin-A and endothelin-B receptors on nociceptive information transmission in the spinal cord with FR139317, an endothelin-A receptor antagonist, and sarafotoxin S6c, an endothelin-B receptor agonist. J. Pharmacol. Exp. Ther. 271:1994;156-163.
56. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
57. Yoshida H., Ohhara M., Ohsumi K. Production of endothelin-1 by cultured human synoviocytes. Clin. Chim. Acta. 259:1997;187-189.